New Website Provides Doctors and Patients Timely Information on Avoiding and Detecting Flu and Other Respiratory Viruses

AUSTIN, Texas--(BUSINESS WIRE)--Oct. 14, 2009-- Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, has launched a new website: www.xTAGRVP.com. The website was created as a resource for physicians and patients seeking information on influenza and other respiratory viruses, as well as the diagnostic testing options available to detect respiratory viruses today. In addition, the www.xTAGRVP.com website offers the latest information on Luminex’s xTAG® RVP Respiratory Viral Panel (RVP), a comprehensive multiplexed test for the detection of multiple viral strains and subtypes.

“We are entering one of the most unpredictable flu seasons we have seen in years, and there are questions and uncertainty in the medical community and the general public alike,” said Nancy Krunic, Ph.D., vice president of Luminex Molecular Diagnostics. “People have concerns, such as ‘What will the next few months bring?’ ‘How can I protect my family?’ ‘How can I know what virus I have?’ In response, Luminex has created a central online resource for physicians and patients to find answers to their questions regarding different types of viruses and testing options. The new xTAGRVP.com website is a user-friendly tool for concerned parties seeking to gather information about how to avoid, identify and recover from influenza and other respiratory viruses that we’ll see circulating over the next few months. The website also provides an overview of the many testing options that are available.”

The www.xTAGRVP.com website is separated into two sections: one addressing physician needs and one specifically designed for patients.

The physician section of the site focuses on respiratory virus testing and the technologies that can be used to detect them. Additionally, the site features a special section on xTAG RVP and 2009 Influenza A/H1N1 or “swine flu.” Case studies of physician’s real-life experiences utilizing xTAG RVP are available for download, as well as links to several peer-reviewed publications and scientific posters.

The patient section of www.xTAGRVP.com provides the latest information about flu and respiratory viruses, how to avoid infection, and what to look for in the newest tests and treatments. It describes the different types of respiratory viruses that can circulate in communities and details common symptoms for each. The website also provides a glossary of respiratory virus-related terms and a frequently asked questions section.

xTAG RVP was developed by Luminex Molecular Diagnostics. The test was cleared by the U.S. Food and Drug Administration (FDA) in January 2008.

More information about xTAG RVP can be found at www.xTAGRVP.com or http://www.luminexcorp.com/rvp.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.

Source: Luminex Corporation

Luminex Corporation
Corporate:
Harriss T. Currie, 512-219-8020
Vice President, Finance and Chief Financial Officer
hcurrie@luminexcorp.com
or
Investor Relations:
Mimi Torrington, 512-219-8020
Director of Investor Relations
mtorrington@luminexcorp.com
or
Media:
Nicole L. Cottrill, 615-327-7999
ncottrill@seigenthaler.com